Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group.

Abstract

Twenty patients with advanced or recurrent leiomyosarcoma of the uterus who failed prior chemotherapy were placed on study by the Gynecologic Oncology Group. One patient had insufficient data to permit analysis. Of the remaining 19, there was only one objective response to cisplatin 50 mg/m2 intravenously every 3 weeks. Although toxicity was tolerable, there is little evidence of drug activity in patients with leiomyosarcomas of the uterus when the drug is given as second-line chemotherapy in the dose and schedule tested.